DOC

DOC

DOC

Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

This is a commonly used substance with well known and widely available human consumption data. This does not guarantee that the substance will be safe. The safety profile has been established based on usage data commonly available.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.

Description

DOC

Also known as:

  • 1-(4-Chlor-2,5-dimethoxyphenyl)-2-propanamin[German][ACD/IUPAC Name]
  • 1-(4-Chloro-2,5-dimethoxyphenyl)-2-propanamine[ACD/IUPAC Name]
  • 1-(4-Chloro-2,5-diméthoxyphényl)-2-propanamine[French][ACD/IUPAC Name]
  • 1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine
  • 2,5-dimethoxy-4-chloroamphetamine
  • 4-chloro-2,5-dimethoxyamphetamine
  • Benzeneethanamine, 4-chloro-2,5-dimethoxy-α-methyl-[ACD/Index Name]
  • DOC
  • 1- (4-chloro-2,5-dimethoxyphenyl) propan-2-amine[ACD/IUPAC Name]
  • '123431-31-2
  • 2-(4-Chloro-2,5-dimethoxy-phenyl)-1-methyl-ethylamine
  • 4-Chloro-2,5-Dimethoxyamphetamine (''DOC'') - from SFL5
  • amphetamine, 4-chloro-2,5-dimethoxy-
  • http://en.atomaxchem.com/123431-31-2.html
  • MFCD12964184[MDL number]

A potent stimulating psychedelic with a long action, a phenethylamine and substituted amphetamine. Sometimes sold as LSD but also enjoyed on its own merits by many. Usually sold on blotters slightly larger than those LSD is found on, but can also be bought in powder form.

Summary

It is a member of the DOx family of psychedelic amphetamines, which are known for their long duration and mixture of psychedelic and stimulant effects. DOC was first synthesized by a team at the University of Alberta in 1972. However, its usage in humans was not popularized until the 1991 publication PiHKAL ("Phenethylamines I Have Known And Loved") by Alexander Shulgin.

Preceding this, a 1989 forensic analysis of designer amphetamine samples identified DOC in Canadian drug seizures. DOC is known as a highly dose-sensitive psychedelic that is often sold in powder form or on blotting paper and known for its long duration (over 12-24 hours), strong visual effects, a unique form of stimulation, and a significant body load. Along with its sensitive dose-response and unusually long duration, many reports also suggest that this substance may be overly difficult to use safely for those who are not already very experienced with hallucinogens.

Therefore it is highly advised to approach this unusually dose-sensitive, and long-lasting psychedelic substance with the proper amount of precaution and harm reduction practices if choosing to use it.

History

You can help by expanding it.

DOC was first synthesized by 1972 by Ronald Coutts and Jerry Malicky at the University of Alberta. While human usage was popularized by the 1991 publication of its synthesis and pharmacology in PiHKAL (“Phenethylamines I Have Known And Loved”) by Alexander Shulgin, a 1989 forensic analysis of designer amphetamine samples identified DOC in Canadian drug seizures.

Chemistry

DOC

DOC

Amphetamines are substituted phenethylamines containing a phenyl ring bound to an amino (NH2) group through an ethyl chain and a methyl group bound to the alpha carbon Rα.

DOC contains methoxy functional groups OCH3 attached to carbons R2 and R5 and a chlorine atom attached to carbon R4 of the phenyl ring.

DOC is the amphetamine analogue of the phenethylamine 2C-C.

Common Name4-chloro-2,5-dimethoxyamphetamine
Systematic name4-chloro-2,5-dimethoxyamphetamine
FormulaC_{11}H_{16}ClNO_{2}
SMILESCC(Cc1cc(c(cc1OC)Cl)OC)N
Std. InChiInChI=1S/C21H30O3/c1-20-9-7-14(23)11-13(20)3-4-15-16-5-6-18(19(24)12-22)21(16,2)10-8-17(15)20/h11,15-18,22H,3-10,12H2,1-2H3/t15-,16-,17-,18+,20-,21-/m0/s1
Std. InChiKeyZESRJSPZRDMNHY-YFWFAHHUSA-N
Avg. Mass229.7032 Da
Molecular Weight229.7032
Monoisotopic Mass229.08696 Da
Nominal Mass229
ChemSpider ID472008

Subscribe for the latest updates

Dosing Guide

Oral
Light1-1.5mg
Common1.5-2mg
Strong2-4mg
Heavy4mg+

Duration

DOC Duration Data
Onset30-150 minutes
Duration10-20 hours
After-effects6-12 hours

Interactions and Synergies

Caution

  1. Mescaline
  2. NBOMes
  3. 2C-x
  4. 2C-T-x
  5. 5-MeO-xxT
    • The 5-MeO class of tryptamines can be unpredictable in their interactions, particularly increasing the risk of unpleasant physical side effects.
  6. Cannabis
    • Cannabis has an unexpectedly strong and somewhat unpredictable synergy with psychedelics.
  7. MXE
    • As an NMDA antagonist MXE potentiates DOx which can be unpleasantly intense
  8. MDMA
    • The combined stimulating effects of the two can be uncomfortable. Coming down on the MDMA while the DOx is still active can be quite anxiogenic.
  9. Caffeine
    • High doses of caffeine may cause anxiety which is less manageable when tripping, and since both are stimulating it may cause some physical discomfort.
  10. MAOIs
    • MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably

Dangerous

  1. DXM
    • The DOx class as psychedelic stimulants have the potential to mask the effects of DXM and could lead to redosing to an unsafe level. DXM can also potentiate DOx resulting in an unpleasantly intense experience.
  2. PCP
    • Details of this combination are not well understood but PCP generally interacts in an unpredictable manner.
  3. Amphetamines
    • The combined stimulating effects of the two can lead to an uncomfortable body-load, while the focusing effects of amphetamine can easily lead to thought loops. Coming down from amphetamines while the DOx is still active can be quite anxiogenic.
  4. Cocaine
    • The combined stimulating effects of the two can lead to an uncomfortable body-load, while the focusing effects of cocaine can easily lead to thought loops. Coming down from cocaine while the DOx is still active can be quite anxiogenic
  5. Tramadol
    • Tramadol is well known to lower seizure threshold and psychedelics also cause occasional seizures.

Low Synergy

  1. Alcohol
    • Drinking on stimulants is risky because the sedative effects of the alcohol are reduced, and these are what the body uses to gauge drunkenness. This typically leads to excessive drinking with greatly reduced inhibitions, high risk of liver damage and increased dehydration. They will also allow you to drink past a point where you might normally pass out, increasing the risk.
  2. GHB/GBL
  3. Benzodiazepines
  4. SSRIs

No Synergy

  1. Opioids
    • No unexpected interactions.

High Synergy

  1. Mushrooms
  2. LSD
  3. DMT
  4. Ketamine
    • Ketamine and psychedelics tend to potentiate each other - go slowly.
  5. N2O

General Information

Experiences
Oral
Vaporization
Come up
Dosage
EffectsEuphoria, empathy, insight, brightened colour, Closed/Open eye visuals, enhanced tactile sensation, mental/physical stimulation, decreased appetite, pupil dilation, restlessness, change in perception, ego softening, sweating/chills, muscle tension, confusion, insomnia.
After Effects
Avoid
Warning
Risks
Test Kits
Marguis Test Result
Tolerance
Detection
Half-life
Advice
Note
Note 2:
Note 3:

Effects

Pharmacological Effects

DOC’s psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective Effects

Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical Effects

  • Stimulation - DOC is usually reported to be extremely stimulating at levels which are capable of becoming uncomfortable and overwhelming. This can result in a shakiness and unsteadiness of the hands but encouraging one to move around, run, dance, climb and generally engage in physical activities. In comparison, other more commonly used psychedelics such as psilocin are generally sedating and relaxed. The type of stimulation is generally encouraged but can also present some forcefulness to it.
  • Spontaneous bodily sensations - The "body high" of DOC is manifested as somewhat intense in comparison to most classical psychedelics such as LSD. The sensation itself can be described as a constantly present yet somewhat mild energetic pins and needles sensation that encompasses a person’s entire body. It is usually felt over every square inch of the skin, but occasionally manifests itself in the form of a continuously shifting tingling sensation that travels up and down the body in spontaneous waves.
    • Physical euphoria - It should be noted that this effect is not as reliably induced as it is with substances like stimulants or entactogens, and can just as easily manifest as physical discomfort without any apparent reason. DOC and other psychedelic amphetamines tend to lean towards physical dysphoria more so than other psychedelics.
  • Changes in felt bodily form
  • Bodily control enhancement
  • Tactile enhancement - Feelings of enhanced tactile sensation are consistently present at low to moderate levels throughout most DOC experiences.
  • Nausea - Mild to extreme nausea is reported when consumed in moderate to high dosages and either passes once the person has vomited or gradually fades by itself as the peak sets in.
  • Vasoconstriction - This effect is usually only present at higher dosages, but can be particularly uncomfortable when it manifests, and may persist throughout as well as after the main duration of the experience.
  • Increased blood pressure
  • Increased heart rate
  • Appetite suppression
  • Increased perspiration
  • Muscle contractions
  • Muscle spasms
  • Muscle cramps
  • Difficulty urinating
  • Dehydration
  • Dry mouth
  • Temperature regulation suppression - This effect is more prominent than it is with other psychedelics like LSD.
  • Diarrhea
  • Teeth grinding
  • Restless legs
  • Pupil dilation
  • Increased salivation
  • Seizure - This is a rarely observed effect but is known to happen in those who are presumably predisposed to them, especially while in physically taxing conditions such as being dehydrated, undernourished, overheated, or generally fatigued.

Psychological Effects

The cognitive effects of DOC are described by many as characterized as prominent mental stimulation combined with a powerful amplification of the user's current mental state. The total sum of these cognitive components regardless of the setting generally includes:

  • Anxiety & Paranoia - This effect is not as common at low to moderate doses and is less likely to occur when the basic rules of set and setting are taken into account. It should be noted that this inconsistently induced effect is seemingly more likely to manifest when used with cannabis. This combination should be used with extreme caution if one is not experienced with psychedelics, meaning that the user should adequately pace themselves with a fraction of their usual amount. It is commonly reported that psychedelics can to a certain extent counteract some of the perceived mental cloudiness or intoxicating effects of THC causing the user to in turn use more cannabis than is needed which can often lead to an overwhelmingly anxious and paranoid headspace which can trigger a "bad trip".
  • Conceptual thinking
  • Thought acceleration
  • Thought connectivity
  • Empathy, affection, and sociability enhancement - This component is typically manifested only in the context of social settings in which one is within the company of others, and only at lower, non-impairing doses. These feelings of sociability, affection, and empathy tend to be weaker and less consistent than those produced by substances such as MDMA and 2C-B, but can still prove strong enough to provide long-lasting therapeutic effects.
  • Cognitive euphoria
  • Analysis enhancement - This effect is consistent in its manifestation and outrospection dominant.
  • Novelty enhancement
  • Immersion enhancement
  • Emotion enhancement
  • Increased music appreciation
  • Increased sense of humor
    • Laughter fits - This can manifest prominently during a DOC experience, particularly during the come up phase, often resulting in bouts of uncontrollable giggles and laughter that can form a feedback loop if around others who are also under the influence.
  • Memory suppression
    • Ego death - While DOC is technically able to produce states of ego dissolution, it tends to more often than not develop only in extremely high doses, with grave physical and mental side effects being apparent and is often of a terrifying nature.
  • Increased libido
  • Time distortion
  • Wakefulness

Visual Effects

The visuals of DOC are commonly described as being very simplistic, cartoon-like and linear, when compared to DOB or LSD.

Enhancements

Distortions

Geometry

The visual geometry encountered on DOC can be described as more similar in appearance to that of mescaline than that of ayahuasca, psilocybin mushrooms or LSD. It can be comprehensively described through its variations as intricate in complexity, abstract in form, synthetic in feel, structured in organization, brightly lit, multicolored in scheme, glossy in shading, sharp in edges, large in size, fast in speed, smooth in motion, equally rounded and angular in its corners, non-immersive in depth and consistent in intensity. At higher dosages, this geometry is significantly more likely to result in states of level 8B visual geometry over level 8A.

Hallucinatory states

DOC and other substituted amphetamines produce a full range of high-level hallucinatory states in a fashion that is more or less consistent and reproducible than that of many other commonly used psychedelics. These effects include:

Auditory Effects

Sensory Effects

  • Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience for those who are already predisposed to synaesthetic states.

Transpersonal Effects

Legal Status

  • Austria: DOC is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
  • Canada: DOC is Schedule I in Canada, making it illegal to sell, buy, or possess, without a valid legal exemption.
  • China: As of October 2015 DOC is a controlled substance in China.
  • Denmark: DOC is a Schedule I drug in Denmark.
  • Finland: DOC is illegal to possess, produce and sell in Finland.
  • Germany: DOC is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of February 1, 1997. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
  • Israel: The possession, production and sale is illegal.
  • Latvia: DOC is a Schedule I controlled substance.
  • New Zealand: DOC is a Class C drug in New Zealand.
  • United Kingdom: DOC is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.
  • United States: DOC is technically not scheduled in the United States, but could be considered an analogue of DOM or DOB and may therefore be considered a Schedule I drug under the Federal Analogue Act.

  • References

    1. Coutts, Ronald T; Malicky, Jerry L. (1973). "The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM)". Canadian Journal of Chemistry, 1973, 51(9): 1402-1409, 10.1139/v73-210 | http://www.nrcresearchpress.com/doi/abs/10.1139/v73-210
    2. http://www.erowid.org/library/books_online/pihkal/pihkal.shtml
    3. Brian A. Dawson & George A. Neville (1989) "Identification of Two New 'Designer' Amphetamines by NMR Techniques", Canadian Society of Forensic Science Journal, 22:2, 195-202, https://doi.org/10.1080/00085030.198
    4. Coutts, Ronald T; Malicky, Jerry L. (1973). "The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM)". Canadian Journal of Chemistry, 1973, 51(9): 1402-1409, 10.1139/v73-210 | http://www.nrcresearchpress.com/doi/abs/10.1139/v73-210
    5. Brian A. Dawson & George A. Neville (1989) "Identification of Two New 'Designer' Amphetamines by NMR Techniques", Canadian Society of Forensic Science Journal, 22:2, 195-202, DOI: 10.1080/00085030.198 | http://www.tandfonline.com/doi/abs/10.1080/00085030.1989.10757433
    6. http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=64
    7. https://www.ncbi.nlm.nih.gov/pubmed/25217551/
    8. https://www.ncbi.nlm.nih.gov/pubmed/25553227/
    9. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
    10. http://portal.anvisa.gov.br/documents/10181/3115436/(1)RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
    11. Controlled Drugs and Substances Act (S.C. 1996, c. 19) | http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html
    12. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
    13. "Neunte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
    14. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
    15. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
    16. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
    17. Misuse of Drugs Act 1971 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I

    Resources

    1. 1717 CheMall DR001559
    2. ACToR: Aggregated Computational Toxicology Resource 64-85-7
    3. AK Scientific N730
    4. AKos AKOS005111365
    5. Alfa Chemistry 64-85-7
    6. American Custom Chemicals Corp SHG0000224
    7. Aronis c07897
    8. Aurora Fine Chemicals K04.013.154
    9. BGS International BG01619481
    10. BIND (no longer updated) 1585
    11. BindingDB 8582
    12. BioCyc 11-DEOXYCORTICOSTERONE
    13. Biological Magnetic Resonance Data Bank bmse000535
    14. Biosynth W-104814
    15. Biosynth Carbosynth FD21043
    16. BOC Sciences 64-85-7
    17. Boerchem BC226378
    18. Cayman Chemical 22916
    19. Cayman Chemical 22916.0
    20. ChEBI
    21. ChEBI CHEBI:16973
    22. ChemBank Prestwick0_000957
    23. ChemBank Prestwick1_000957
    24. ChemBank SPBio_003103
    25. ChEMBL CHEMBL1498
    26. ChemIDplus 000064857
    27. ChemPedia 5-8610-1689-3271
    28. ChemScene 64-85-7
    29. Collaborative Drug Discovery 192
    30. DiscoveryGate 6166
    31. DSigDB d3_574
    32. DSigDB d3_575
    33. DSigDB d4ctd_5776
    34. eMolecules 510143
    35. eNovation Chemicals K61307
    36. EPA DSSTox DTXCID8025254
    37. FDA UNII - NLM 40GP35YQ49
    38. FDA UNII - NLM UNII: 40GP35YQ49
    39. Finetech Industry FT-0603104
    40. FooDB FDB006404
    41. FooDB FDB021873
    42. Glentham Life Sciences GL4964
    43. Golm Metabolome Database BD5D7BC9-0CD8-404E-9BA0-F670962012F8
    44. Guide to PHARMACOLOGY 2871
    45. Human Metabolome Database HMDB00016
    46. Infotherm 27761
    47. Jean-Claude Bradley Open Melting Point Dataset 17231
    48. Jean-Claude Bradley Open Melting Point Dataset 28011
    49. Jean-Claude Bradley Open Melting Point Dataset 28012
    50. Jean-Claude Bradley Open Melting Point Dataset 28013
    51. KEGG C03205
    52. KEGG D07792
    53. LabNetwork LN01268026
    54. Laboratory Chemical Safety Summary 6166
    55. LeadScope LS-59472
    56. LGC Standards DRE-C14241050
    57. MassBank JP005729
    58. MassBank JP009696
    59. Mcule MCULE-4728366427
    60. Mcule MCULE-4839802180
    61. MMDB 107155
    62. MMDB 33237
    63. MMDB 33237.3
    64. MMDB 34430
    65. MMDB 34430.3
    66. MMDB 40219
    67. MMDB 59380
    68. MMDB 91464
    69. MP Biomedicals 203891
    70. MuseChem R053089
    71. PDB 1CA
    72. PIChemicals PI-19807
    73. PlantCyc 11-DEOXYCORTICOSTERONE
    74. PubChem 6166
    75. PubMed 11129951
    76. PubMed 1195280
    77. PubMed 12127495
    78. PubMed 12798173
    79. PubMed 14519458
    80. PubMed 16223868
    81. PubMed 17151189
    82. PubMed 17252366
    83. PubMed 1981529
    84. PubMed 1997119
    85. PubMed 3217959
    86. PubMed 3217960
    87. PubMed 5822948
    88. PubMed 6313164
    89. PubMed 6482428
    90. PubMed 6708539
    91. PubMed 6851944
    92. PubMed 702293
    93. PubMed 9237422
    94. Rosewachem RW0167645
    95. Rostar Global RS-2434603
    96. RSC Learn Chemistry Wiki 11-Deoxycorticosterone
    97. Sabio-RK 26473
    98. Sabio-RK 6485
    99. Santa Cruz Biotechnology sc-231274
    100. Sigma-Aldrich D6875
    101. Sigma-Aldrich SIGMA-D6875
    102. SMPDB Small Molecule Pathway Database HMDB00016
    103. SMPDB Small Molecule Pathway Database PW_C000010
    104. Springer Nature Steroidogenesis in Patients with Various Adrenal Cortex Diseases as Studied by Reversed-Phase High-Performance Liquid Chromatography
    105. The Merck Index Online cs000000006846
    106. Thieme Chemistry SD-026-00847
    107. Thomson Pharma 00020611
    108. Thomson Pharma 00062628
    109. Toxin, Toxin-Target Database T3D4245
    110. VulcanChem VC248937
    111. Wikidata Q948846
    112. Wikipedia 11-Deoxycorticosterone
    113. Yuhao Chemical RT19577
    114. ZINC ZINC03833823

    Sources

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.